{
    "title": "Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-NaiÌˆve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study",
    "pmid": "26715213",
    "pmcid": "PMC4916189",
    "study_parameters": [
        {
            "Study Parameters ID": 1448993785,
            "Variant Annotation ID": 1448993783,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 569.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.016",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993783"
        },
        {
            "Study Parameters ID": 1448993769,
            "Variant Annotation ID": 1448993767,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 573.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993767"
        },
        {
            "Study Parameters ID": 1448993796,
            "Variant Annotation ID": 1448993794,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 570.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.008",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993794"
        },
        {
            "Study Parameters ID": 1448993766,
            "Variant Annotation ID": 1448993759,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 546.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.42",
            "Ratio Stat Type": "OR",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993759"
        },
        {
            "Study Parameters ID": 1448993833,
            "Variant Annotation ID": 1448993831,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 606.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.006",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.14,
            "Confidence Interval Start": 1.25,
            "Confidence Interval Stop": 3.67,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993831"
        },
        {
            "Study Parameters ID": 1448993812,
            "Variant Annotation ID": 1448993810,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 606.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.3,
            "Confidence Interval Start": 0.12,
            "Confidence Interval Stop": 0.75,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993810"
        },
        {
            "Study Parameters ID": 1448993822,
            "Variant Annotation ID": 1448993820,
            "Study Type": "cohort, clinical trial",
            "Study Cases": 606.0,
            "Study Controls": null,
            "Characteristics": null,
            "Characteristics Type": "Unknown",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.011",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.59,
            "Confidence Interval Start": 1.11,
            "Confidence Interval Stop": 2.27,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448993820"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1448993783,
            "Variant/Haplotypes": "CYP2B6*1, CYP2B6*9",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Efficacy",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.",
            "Alleles": "*9",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Discontinuation",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "*1/*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993783"
        },
        {
            "Variant Annotation ID": 1448993767,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Efficacy",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
            "Alleles": "GT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Discontinuation",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993767"
        },
        {
            "Variant Annotation ID": 1448993794,
            "Variant/Haplotypes": "rs2472677",
            "Gene": "NR1I2",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Efficacy",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.",
            "Alleles": "TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Discontinuation",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC + CT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993794"
        },
        {
            "Variant Annotation ID": 1448993759,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Efficacy",
            "Significance": "no",
            "Notes": "This is not associated with virological endpoint (achieving pVL < 200 copies/mL).",
            "Sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.",
            "Alleles": "T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Efficacy:virological response",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "G",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993759"
        },
        {
            "Variant Annotation ID": 1448993831,
            "Variant/Haplotypes": "rs1045642",
            "Gene": "ABCB1",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
            "Alleles": "AA",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Central Nervous System Disorder",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "GG",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993831"
        },
        {
            "Variant Annotation ID": 1448993810,
            "Variant/Haplotypes": "rs28399499",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.",
            "Alleles": "CC + CT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Central Nervous System Disorder",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "TT",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993810"
        },
        {
            "Variant Annotation ID": 1448993820,
            "Variant/Haplotypes": "rs4803419",
            "Gene": "CYP2B6",
            "Drug(s)": "efavirenz",
            "PMID": 26715213,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": null,
            "Sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.",
            "Alleles": "CT + TT",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Central Nervous System Disorder",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "CC",
            "Comparison Metabolizer types": null,
            "PMID_norm": "26715213",
            "Variant Annotation ID_norm": "1448993820"
        }
    ],
    "var_fa_ann": []
}